The ‘Green Tide’: Argentinians demanding the legalisation of abortion.

The movie “Belén”, Argentina’s submission for the 2026 Oscars, tells the story of a 26-year-old woman who suffered a miscarriage in a hospital in Tucuman province in 2014 and was sentenced to eight years in prison in 2016 after being convicted of procuring an illegal abortion. 

Her case sparked a nationwide campaign to decriminalize abortion, known as the Green Tide after the green scarves protestors wore.

In December 2020, the Green Tide won: abortion was legalized on request up to 14 weeks, and later in cases of rape or risk to the woman’s physical or mental health.

Between 1985 and 2016, unsafe abortions caused 3,040 deaths –  29% of all maternal deaths – and more than 50,000 hospitalizations each year, according to the Argentinian Ministry of Health (MoH).

The rollout of the new policy was swift: from January 2021 to December 2024, Argentina’s public health system performed 314,500 legal abortions.

“Belen” is making waves in festivals. But in every interview, director Dolores Fonzi warns that this hard-won right is being eroded under President Javier Milei, elected in December 2023.

‘Murderous abortion agenda’

Milei combines radical economic libertarianism, aggressive austerity to reduce the state’s size and scope, and conservative, anti-feminist rhetoric.

At the 2024 World Economic Forum in Davos, Milei blasted “the bloody, murderous abortion agenda” that, he claimed, promotes population control to save the earth and has spurred falling fertility rates worldwide. He also condemned the  “sinister agenda of wokeism” and “LGBT ideology”.

Very quickly, his administration set out to dismantle reproductive rights programmes.

In February 2024, a representative from Milei’s party, Liberty Advances (LLA, from its Spanish acronym), introduced a bill to repeal the 2020 abortion law. It re-criminalized abortion for both the practitioner and the pregnant woman, with no exception for rape. 

Faced with public outrage, the Bill was quickly withdrawn. Abortion is not a priority for now, said Vice-President Victoria Villaruel, a conservative Catholic.

The government’s words and actions have created “an extremely complicated environment to access reproductive rights,” said Insist and Persist, a watchdog report in December 2024.

Budget cuts undermine access

Without repealing the law, however, the new administration has undermined reproductive health and rights programmes by throttling finances. The federal health budget has been slashed by 48% in real terms, and the provision of contraceptives and pregnancy tests to provinces was cut by 81%.

The safe abortion programme took a major hit. In 2024, the federal Ministry of Health (MoH) abruptly stopped distributing pregnancy tests, medicines and supplies for abortion care to the provinces, including 106,000 units of the medical abortion pills, misoprostol and mifepristone, scheduled for delivery.

Suddenly, each province, with varying levels of skills and budgets for procurement, had to buy its own supplies. The big discounts for pooled national procurement were lost.

By late 2024, half the provinces faced shortages of misoprostol, and nearly all had run out of mifepristone and combipacks of the two drugs that are used for medical abortions, according to Amnesty International in its 2025 report “It’s about you too: Defending access to abortion amid the rollback of public policies”.

The MoH also stopped releasing data about abortion, complications and procurement in 2024, and such information must be obtained through legal requests.

The MoH also froze training and technical assistance for safe abortion, a critical setback for provinces with many health workers who are conscientious objectors and too few trained providers. These measures deepened geographical and economic inequalities in access to reproductive health between rich and poor provinces.

The Milei government has slashed resources for reproductive health services.

Patients forced to pay

The MACA survey (Measuring Access and Quality of Abortion, 2023-2025, in six provinces) found that, although the procedure should be free, nearly half of users paid out of pocket, mainly for ultrasounds.

Complaints filed on Amnesty’s online form about barriers to access abortion nearly tripled in 2024, compared to 2023.

Users reported having to buy medicines and pay for ultrasounds. “Maria”, an informal worker with four children, was told to buy misoprostol for $73 – more than her monthly earnings. Finding a clinic with time slots and no costs took time, money and anxiety.

Delays occurred at every stage: consultations and medications were postponed (18%), waiting periods exceeded the 10 days allowed by law (62%), and in some cases, the procedures went beyond the legal 14-week limit. The MoH 0800 information line is not widely advertised and often goes unanswered. 

Alarmingly, private Centres for Vulnerable Maternities, which are not part of the MoH, have popped up in public hospitals to provide anti-abortion counselling.  Users reported misinformation about abortion effects, invasion of privacy, aggressive questioning, and harassment through unwanted follow-up calls.

For example, at the Centre in San Isidro Hospital in Buenos Aires, a woman said she was shown a doll, asked why she wanted “to kill her baby”, and asked how many sexual partners she had.

In many parts of the world, “crisis pregnancy centres” – usually funded by US organisations – have been set up to scare pregnant women seeking abortions, according to several exposés by openDemocracy.

Teen pregnancy plan dismantled

A crucial component in abortion reduction, the successful national plan to prevent unintended adolescent pregnancies (ENIA), was dismantled, its budget cut by 64% in 2024 compared to 2033, and 619 staff dismissed. 

Deliveries of supplies to high-priority provinces, from condoms to emergency contraception, dwindled, with long-acting subdermal contraceptive implants plunging from 76,000 in 2023 to barely 4,200 in 2024.

Active since 2017 in 12 of the country’s 23 provinces, ENIA helped cut teen pregnancy by nearly half between 2018 and 2022, especially among the poorest, least educated teenagers. ENIA prevented an estimated 94,000 unintended pregnancies, according to UNFPA.

On the positive side, Project Watch notes that provinces showed commitment to Law 27.610 by procuring essential medicines and supplying information. Mendoza province expanded access by allowing licensed midwives to provide voluntary abortion services.

Public support for reproductive health runs strong. A 2024 survey found that 70% of Argentinians agreed that the federal government should provide contraceptives and support the prevention of sexually transmitted infections (STIs) and teen pregnancy.

Rising evangelical influence

But in October, Milei’s LLA won a key mid-term legislative election with nearly 41% of the vote (31% for the opposition, 32% abstention).  Among the LLA’s elected lawmakers are six evangelical Christians, chief among them new senator Nadia Marquez, a lawyer and pastor who has called abortion “the largest genocide in history”. Marquez campaigned against the law’s approval and has vowed to get it repealed.  About 15% of Argentinians are evangelicals.

In early November,  Milei and top Cabinet members hosted American preacher Franklin Graham at Casa Rosada, the seat of government. Graham, a key religious supporter of US President Donald Trump and long-term campaigner against abortion and same-sex relationships, hosted two well-supported rallies in Buenos Aires last month.

Although LLA would not have the votes required to repeal the law now, abortion care and rights are likely to face further restrictions.

Bill Gates, WHO Director General Dr Tedros Adhanom Ghebreyesus and other global leaders at Monday’s polio eradication pledging event in Abu Dhabi.

Global leaders pledged US$ 1.9 billion to advance polio eradication on Monday, including a new $1.2 billion commitment by the Gates Foundation.

The pledges, made on the margins of Abu Dhabi  Finance Week, reduce the remaining budget gap for the Global Polio Eradication Initiative’s (GPEI) to just $440 million through 2029.  That’s in comparison by the $2.3 billion funding gap that had been faced in May, at the time of the World Health Assembly, following the withdrawal of the United States from WHO, a major GPEI partner in early 2025.  See related story:

Polio Eradication Imperiled by $2.3 Billion Funding Gap

“The funds will accelerate vital efforts to reach 370 million children each year with polio vaccines, alongside strengthening health systems in affected countries to protect children from other preventable diseases,” said GPEI in a press release Monday.

Along with the Gates pledge, some $450 million was pledged by Rotary International, another leading GPEI partner along with WHO; $154 million from Pakistan; $140 million from the United Arab Emirates’s Mohamed bin Zayed Foundation; $100 million from Bloomberg Philanthropies; $62 million from Germany; and $46 million from the United States. Smaller amounts were pledged by Japan, Luxembourg and other foundations.

The pledge by the US, traditionaly GPEI’s second largest donor, was only a fraction of past years contributions. In 2023 alone, for instance, the US contributed some  $230 million – funneling roughly half of the funds directly to GPEI as well as through WHO.

Annual donations to global polio eradication broken down by country, foundation and international bloc for 2023.

In October 2024, the Polio Oversight Board approved an expanded multi-year budget totalling US$ 6.9 billion for 2022-2029.  That represented a substantial increase in the $4.8 billion projected for 2022-2026.  It simultaneously extended timeline for wild poliovirus eradication to 2027, and for the Type 2 vaccine-derived poliovirus variant to the end of 2029.

The wildvirus saw a sharp resurgence in conflict-ridden Afghanistan  and Pakistan in 2024. Vaccine-derived poliovirus variants, meanwhile, emerged or re-emerged in 35 countries across Africa, Asia and the Middle East, and even Spain – also as a result of conflict, migration and under-vaccination.

The 2026 GPEI budget is now pegged at some $786.5 million. The multi-year budget will be revised in review of progress in 2026, GPEI said.

The new Gates Foundation pledge was not unexpected following the announcement by the tech leader and philanthropist Bill Gates earlier this year that he intended to give away all of his fortune and drain his foundation’s endowment, estimated at around $200 billion, within the next 20 years.

Speaking to the UAE newspaper The National during the Abu Dhabi conference, Gates said the Foundation “has a 20-year lifetime and we have very ambitious goals. First to get polio done, but then malaria’s another disease that should be eradicated”. He added: “It’d be wonderful if 30 years from now, people said ‘malaria? What was that? Polio? What was that?”

Image Credits: Global Polio Eradication Initiative , Global Polio Eradication Initiative.

The UNEP report calls for the phasing out and repurposing of fossil fuel subsidies.

A baby born today will turn 75 in 2100, and the world that child will inherit as an adult – if governments don’t act in the next five years – could be 3.9°C hotter, economically shattered, and ravaged by pollution. But there is still a choice, a new United Nations Environment Programme (UNEP) report demonstrates. 

A sustainable, transformative path is still possible with a whole‑of‑government and whole‑of‑society approach, according to the report,  the most comprehensive assessment of the global environment ever undertaken, and the product of 287 multi-disciplinary scientists from 82 countries.

It will require massive investment now that will pay back exponentially, according to UNEP’s 7th Global Environment Outlook (GEO 7), launched this week at the seventh session of the United Nations Environment Assembly (UNEA) at the UNEP headquarters in Nairobi, Kenya.

Climate change, biodiversity loss, land degradation, desertification, and pollution and waste are costing trillions of dollars each year. One million of an estimated eight million species are threatened with extinction, some within decades.

Prof Ying Wang (left) and Sir Robert Watson (right) with UNEP Executive Director Inger Andersen (centre) at the report launch.

Sustainable future?

The Global Environment Outlook lays out a simple choice for humanity: continue down the road to a future devastated by climate change, dwindling nature, degraded land and polluted air, or change direction to secure a healthy planet, healthy people and healthy economies. This is no choice at all,” said Inger Andersen, UNEP Executive Director.

She conceded that transformation will be hard at the launch on Tuesday, but called on all nations “to follow the transformation pathways laid out in the GEO 7 report, and to drive their economies and societies towards a thriving, sustainable future.”

The upfront costs are about $8 trillion annually until 2050 (far more than the $1.3 trillion negotiated currently). But the long-term return is immense. The global macroeconomic benefits start to appear around 2050, grow to $20 trillion a year by 2070, and could boom to $100 trillion per year thereafter.

The human dividend of this best-case scenario is profound. Up to nine million premature deaths could be avoided by 2050 due to decreased pollution, and about 100 million people could be lifted out of extreme poverty. 

“The cost of action is far smaller than the cost of inaction. Our message is simple. Time is running out, but the solution is here,” said Prof Ying Wang of Tongji University in China, one of the lead authors.

Current pathway spells disaster 

As sea levels rise and storms become more intense, more countries will be affected by floods.

The other stark future analysed in the report for a child born today is far worse. If governments stick with existing policies and trends, global average temperature is projected to rise by around 3.9°C by 2100, with a more than even chance of crossing 1.5°C in the early 2030s and 2°C in the 2040s. [The 1.5° threshold represents the global warming limit – relative to pre-industrial average temperature – that the 2015 Paris Agreement established as a key goal.]

On this trajectory, climate change alone would knock about 4% off annual global GDP by mid‑century and roughly 20% by the end of it, largely through crop failures, heat stress, floods and productivity losses, according to the report. 

Sea level could rise by up to two metres in the worst-case scenario, while the economic cost of health damage from pollution-related mortality is projected to increase to between $18-25 trillion by 2060. 

Those numbers sit atop an already dangerous baseline. Human activity has driven greenhouse gas emissions up by about 1.5 % each year since 1990, hitting a record high in 2024, while between 20 and 40 % of the world’s land is now degraded. 

Pollution, especially air pollution, is now “the world’s largest risk factor for disease and premature death”, with health damages from air pollution alone valued at around $8.1 trillion in 2019, about  6 % of global GDP. 

GEO 7 is a scientific assessment and guidance for governments, the private sector, and communities. It sets targets over the next few years and decades on the basis that climate change is an economic, health and ethical issue, not only an environmental one.

Rethinking economies

The report’s core recommendations centre on rethinking how economies measure success. This includes moving away from GDP as the sole metric and adopting broader “inclusive wealth” metrics that track human and natural capital – from clean air and healthy soils to education and public health.

Scientists behind GEO 7 stress that the decisive window is closing fast. To stick to the 1.5°C limit (currently about 1.4 °) in practice means global emissions must peak by 2025 and fall sharply – by about 40 % – by 2030. 

But current national climate pledges fall far short of that, with emissions in 2030 expected to remain close to today’s levels even if governments implement their plans in full.

Each additional fraction of a degree increases the intensity of heatwaves, droughts, floods and storms, along with knock‑on effects on food security, disease spread and mental health. 

To change course, the report calls for nothing less than a rewiring of how economies measure success and how societies consume.  

That shift in accounting, the authors argue, must be backed by hard policy. This involves phasing out and repurposing subsidies that encourage fossil fuel use and other environmentally harmful activities.

It means pricing pollution and other “negative externalities” so that the health and ecosystem costs of coal power, for example, show up in energy bills.

Public and private finance needs to be redirected to clean energy, ecosystem restoration, resilient infrastructure and universal access to basic services. 

These measures are framed not only as climate and nature policy, but as public health interventions that cut exposure to dirty air, unsafe water and toxic chemicals.

“We can no longer support the idea of ‘make money, make money, make money now, and I don’t care what’s happening later’,” says Prof Edgar E. Gutiérrez‑Espeleta, a lead author of GEO‑7 and former Minister of Environment and Energy in Costa Rica. “The main message to businesses is: yes, you can make a good business if you think in a sustainable way.”

Five systems, two pathways

GEO 7’s blueprint revolves around transforming five interconnected systems: economy and finance, materials and waste, energy, food and the wider environment. For each, it sets out concrete levers. 

In materials and waste, that means designing products for durability and repair, improving traceability, building markets for recycled materials and shifting consumption patterns towards reuse and sharing. 

In energy, the report calls for rapid decarbonisation of power and fuels, major gains in efficiency, and an explicit focus on energy access and poverty so that the transition does not leave poorer communities behind.

Food systems need to pivot towards healthy and sustainable diets, more efficient and resilient production, lower food loss and waste, and novel proteins that reduce pressure on land and water. 

On the environmental front, GEO‑7 urges accelerated conservation and restoration of ecosystems, greater use of nature‑based solutions to protect communities from floods and heat, and climate adaptation strategies co‑designed with Indigenous and local communities. 

Behaviour- and technology-led climate action

To navigate these shifts, the report models two “transformation pathways”. One is behaviour‑led: societies choose to place less emphasis on material consumption, adopting lower‑carbon lifestyles, travelling differently, using less energy and wasting less food. 

The other is technology‑led: the world relies more heavily on innovation and efficiency – from renewable power and electric mobility to advanced recycling and precision agriculture – while still curbing the most wasteful forms of consumption. 

Both pathways assume “whole‑of‑government” and “whole‑of‑society” approaches, with policies aligned across ministries and meaningful participation by civil society, business, scientists and Indigenous Peoples.

Despite the detailed roadmap, GEO 7’s authors are frank about the gap between their scenarios and today’s politics. At preparatory talks in Nairobi, governments failed to agree on a negotiated summary for policy makers (SPM) amid disputes over fossil fuels, plastics, the circular economy and burden‑sharing.

“There were a number of issues at the meeting in Nairobi that caused difficulty for some countries,” says Sir Robert Watson, a lead author and a former co‑chair of the Intergovernmental Panel on Climate Change. “Unfortunately, we could not come to an agreement at that meeting for a negotiated summary for policymakers.”

Bleak year for climate action

GEO 7’s call to action comes amid a bleak year for climate action, with the US withdrawal from the Paris Agreement, rising global emissions, and an underwhelming COP30 in Brazil all signalling stalling momentum to address climate change.

Watson points to the stalled global plastics treaty talks and “limited progress” at recent climate and biodiversity negotiations as signs that governments are “not moving fast enough, by any stretch of the imagination, to become sustainable”. 

Nations, particularly big carbon emitters like the US, China, the European Union, India, Indonesia and Brazil, need to take tough and ambitious climate action immediately. 

It won’t be easy in the current geopolitical climate. The authors know this, but are banking on “visionary” countries and some in the private sector to recognise they will make “more of a profit” by addressing these issues rather than ignoring them. 

“A number of governments, including one very powerful government do not believe in addressing issues such as climate change and loss of biodiversity,” Watson says. 

The irony is stark. Several leaders of the big emitter countries are in their seventies. The decisions they make – or refuse to make – in the next five years will determine whether that baby born today inherits a world of deepening crisis or one where investment in planetary health has begun to pay back by the time she turns 75 in 2100. The question is, what world will she see?

Image Credits: UNEP, AP, UNEP.

Former CDC director Dr Susan Monarez testifying to the US Senate after she was fired.

Why the collapse of the wall between science and ideology at the US Centers for Disease Control and Prevention (CDC) threatens national health security, and vulnerable communities.

I have spent most of my professional life in public health, from my work in HIV and meningitis prevention in commercial sex venues in New York City to my roles in leading emergency operations in national and global outbreaks. 

I have seen what happens when misinformation fills the space where science should be–people’s health is put at risk. And today, as partisan political forces reshape what Americans are told about vaccines, infectious disease, and community health, I fear we are watching the same dangerous pattern unfold, and the health and safety of our nation will suffer.

The wall that once protected scientific evidence from political interference did not fall on its own. Its foundation was damaged by miscalculations and miscommunication during extreme threats like the COVID-19 pandemic.  

This damaged wall was then easily pushed down by nefarious actors who moved from the fringes to the top of national health leadership, facilitated by elected officials distracted by politics rather than focused on health. Unless we build a new, stronger wall, resistant to such attack, the consequences will be measured in preventable illness, permanent disability, and lives cut short.

From marginalization to manufactured confusion

For decades, the CDC has been a global gold standard in disease surveillance and immunization guidance. That work relies on a simple principle: CDC and external scientists generate and evaluate evidence. Policy follows the data after close consideration of all the domains to make sure that it supports the optimal health of people. Clear communications express the policy for public health and healthcare professionals and the general public

Over the last year, that sequence has been toppled. Instead of scientific review guiding recommendations, ideological preferences have dictated the conclusions while scientists were either not consulted or told to “find the proof” to support a pre-formulated conclusion.  

CDC subject matter experts have been excluded from substantive briefings with leadership at the Department of Health and Human Services (HHS). Repeated requests for data to support the major changes to the immunization schedule made by secretarial decree have never been delivered. Sweeping changes to scientific documents have been announced without process, review, or the knowledge of the involved agencies.  

The result is not only dysfunction. It is distortion. The changes to immunization policy and science released under the CDC moniker were not produced through the normal, rigorous, transparent process.

They relied on analyses the agency never saw. They contained interpretations of research that the original authors themselves would not support. In some cases, they advanced ideas that have long been rejected by pediatricians, immunologists, virologists, and epidemiologists.

When science is forced to serve ideology, the public receives neither science nor ideology. They receive confusion.

US Health Secretary Robert F Kennedy Jr (right) has disrupted the US immunisation schedule since being appointed by President Donald Trump

Direct threat to vulnerable communities 

When I entered public health, I did so as a gay physician who watched too many friends suffer and die in a system that decided their lives were expendable. That experience shaped my entire career. It taught me that public health is not an abstraction. It is an obligation.

Today, that obligation has been broken. Ideological rhetoric has elevated intuition above science, denying the benefit of vaccines that have saved millions of children from disability and death and focusing on unproven or debunked risks of these vaccines or their components. 

This pivot toward a pre-vaccine worldview is not theoretical. It directly threatens infants, pregnant people, older adults, and immunocompromised individuals who depend on evidence-based recommendations and population immunity.

The consequences do not stop there. The current administration’s dismissal of transgender health, its efforts to halt domestic and international HIV programs, and its disregard for the expertise needed to manage respiratory viruses reveal a worldview centered on survival of the strong rather than protection of the vulnerable.

Eugenics is not a word I use lightly. Yet elements of that thinking are echoed in policies that promote natural infection over prevention provided by vaccines; confound health equity with diversity-focused hiring practices, and pit personal choice against community.

For people who already face barriers to care, such an approach is not only negligent. It is dangerous.  We cannot support systems where only the strong should survive or thrive. Not everyone has the luxury of choice in the circumstances that put them at risk for poor health.

A government that claims to care about the health of its citizens cannot choose which citizens deserve the opportunity to achieve their best health.  

Collapse of trust and credibility

Trust is the currency of public health. Without it, guidance becomes noise. Recommendations become suspicion. Data becomes propaganda.

The recent firing of scientists from the Advisory Committee on Immunization Practices (ACIP) through a social media post instead of direct communication was not just unprofessional. 

It was a public signal that expertise is now secondary to optics and key staffing decisions are being driven by loyalty to an ideology rather than competence.  It is unfathomable that the executive leadership of CDC does not include any career scientists and is staffed entirely by political appointees with little or no public health experience. 

When leaders announce major shifts in COVID recommendations in hastily produced videos or rambling online posts that bypass the agency entirely, the public does not see innovation. They see chaos.

As a public health expert, Dr Demetre Daskalakis has been involved in numerous health campaigns – including on mpox – but says public trust in institutions has been broken.

Once trust is broken, earning it back is not easy. It requires honesty, transparency, and humility. It requires acknowledging mistakes and inviting scrutiny. It requires remembering that the CDC’s credibility comes not from politics but from the dedication of thousands of career scientists who wake up every morning committed to protecting the public.  

CDC scientists continue to work to protect our health, but they are being held hostage in a hijacked agency being manipulated for the political and personal gain of its leadership. 

Where agencies like the CDC go from here

I resigned as Director of the National Center for Immunization and Respiratory Diseases, not because the work was unimportant, but because the work was being undermined at its core. 

As long as scientific staff cannot brief leadership, review data, or provide recommendations free from interference, the CDC cannot fulfill its mission.  

We have come to a point in the history of CDC where we cannot trust its communications.  It has become a wolf in sheep’s clothing: thinly disguising ideology and partisan politics in the garb of CDC-endorsed science and communication.

The path forward requires more than restoring old structures. It requires building a durable firewall between science and political ideology that is strong enough to withstand future attacks.

Three principles must guide that reconstruction:

First: Transparency must be non-negotiable. Data informing national recommendations must be publicly available, subject to peer review, reproducible, and accessible to CDC scientists. No policy should be finalized without the agency scientists responsible for it participating in the analysis

Second: Expertise must be valued, not vilified. Advisory committees like ACIP must be staffed with qualified, vetted experts who are selected based on competence, not ideological alignment with HHS leadership. Their guidance must be generated through a structured scientific process to ensure their recommendations optimize the health of people rather than serve ideology or the personal gain of HHS leaders and their associates. 

Third: Public health must return to its purpose. The goal is not political positioning. It is the protection of people. That includes members of  LGBTQ communities, immigrant communities, rural communities, Indigenous communities, and all who have historically been told their lives matter less.

Public health cannot thrive in secrecy. It cannot operate in fear. And it cannot function when science is treated as an inconvenient truth that can simply be edited out of existence with a tweet or revision of a website. 

Building a new system

 We are not witnessing a disagreement over data or a generative scientific debate. We are experiencing the intentional collapsing of the systems that protects the health of our nation. We are beyond the point of no return with CDC.  

Rather than hoping to rebuild a shattered agency, our effort should focus on building a new public health system that is better equipped to withstand the ideological blows that have damaged trust in the current federal public health system. 

It must be responsive to the needs of the people it serves on the ground rather than the whims of disconnected partisan leaders. Building these systems will require courage, clarity, and commitment from jurisdictional public health, academic, and business leaders who understand that public health science is not a threat to democracy. It is the foundation for the health and economic security of our nation.

The question is not whether we have the knowledge to create the new public health. It is whether we have the will and the courage to leave the past behind and move into the future.

As I wrote in my resignation letter, public health is not merely about the health of the individual. It is about the health of the community, the nation, and the world. The stakes could not be higher.

If ideology continues to replace evidence, we risk returning to an era where only the strong survive. If we choose science, transparency, and compassion, we can build a healthier future for everyone. The choice is ours, the time to act is now.

Dr Demetre Daskalakis, MD, MPH is senior public health advisor for the Wellness Equity Alliance. He is the former Director of the US CDC’s The National Center for Immunizations and Respiratory Diseases, and nationally recognized in the US as an expert in infectious disease, immunization policy, and LGBTQ health.

 

 

Kenyan Cabinet Secretary Musalia Mudavadi and US Secretary of State Marco Rubio sign the health agreement.

As World Health Organization (WHO) member states decided to hold a new round of talks in January on establishing a global pathogen access and benefit sharing (PABS) system, the US signed its first bilateral health agreements, which include pathogen-sharing arrangements, with Kenya and Rwanda late last week.

The WHO talks on PABS, the last remaining outstanding item of the Pandemic Agreement, will resume on 20-22 January but the two main groupings remained far apart by the close of the fourth round of talks on Friday (6 December).

Yet the US Memorandums of Understanding (MOU) with the two African countries – and up to 48 others in the pipeline – potentially undercut any global agreement by giving the US early access to information on dangerous pathogens.

Few parameters for pathogen-sharing are set out in the MOUs, so any agreement reached by WHO member states could still guide African countries when they meet US officials in the coming months to nail down the terms of the MOUs.

However, “no common ground was found on key issues – particularly around benefits predictability and legal certainty in the PABS system” at the WHO talks, according to the Resilience Action Network International (RANI), previously known as the Pandemic Action Network.

During last week’s WHO negotiations, 51 African countries and the Group of Equity, which cuts across all regions, called for the PABS agreement to include model contracts – and submitted three draft contracts for consideration dealing with the obligations of the recipients of pathogen information, the providers of this information, and laboratories.

Africa and the Group of Equity want legal certainty in the PABS system, while the group, mostly developed countries with pharmaceutical industries, cautions against provisions that may hamper private companies or innovation.

“At the centre of this tension lies open access versus traceability,” according to RANI, a key civil society observer of pandemic talks. “Some favour unrestricted access to pathogen data and sequences (for example, without registration), noting it speeds up research and development. Others argue that benefits can only be enforced if use is traceable — and users visible.”

Up to 50 US-African MOUs 

Meanwhile, Rwanda and Kenya – in Washington for the signing of a peace agreement between Rwanda and the Democratic Republic of Congo (DRC) – both signed “health cooperation” MOUs with the US last week.

US Secretary of State Marco Rubio announced during the signing ceremony with Kenya that there were “30 to 40” similar agreements in the pipeline while one of his officials said there were “50”.

The MOUs aim to revive US health aid, including the US President’s Emergency Plan for AIDS Relief (PEPFAR) funding – the pausing of which by the Trump administration earlier this year has severely strained several African countries’ health systems.

In exchange, African countries have to commit to signing a 25-year “specimen sharing agreement”, although the MOUs only cover a five-year grant period. This agreement will cover “sharing physical specimens and related data, including genetic sequence data, of detected pathogens with epidemic potential for either country within five days of detection”. 

According to Article 4 of the model specimen-sharing agreement: “Each Party affirms that its participation in any multilateral agreement or arrangement, including surveillance and laboratory networks, governing access and benefit sharing of human and zoonotic specimens and related data shall not prejudice its compliance with this agreement.”

In other words, countries’ agreements with the US will, at a minimum, be on a par with the global Pandemic Agreement and its PABS annex. The US withdrew from the WHO on 20 January, the day Donald Trump assumed the presidency.

Kenya’s President William Ruto applauds Kenyan Cabinet Secretary Musalia Mudavadi and US Secretary of State Marco Rubio.

US-Kenya agreement

The US “plans to provide up to $1.6 billion over the next five years to support priority health programs in Kenya including HIV/AIDS, tuberculosis (TB), malaria, maternal and child health, polio eradication, disease surveillance, and infectious disease outbreak response and preparedness”, according to a statement by the US State Department.

Over the same period, Kenya “pledges to increase domestic health expenditures by $850 million to gradually assume greater financial responsibility as US support decreases over the course of the framework”.

Kenya will assume responsibility the “procurement of commodities” and employing frontline healthworkers. It will also scale up its health data systems, in part to provide the US with accurate statistics about priority diseases, and develop systems to reimburse faith-based and private sector service providers directly, according to the statement.

Former DOGE leader Brad Smith, now senior advisor for the Bureau of Global Health Security and Diplomacy at the US Department of State, described the agreement with Kenya as “a model for the types of bilateral health arrangements the United States will be entering into with dozens of countries over the coming weeks and months”.

An earlier leaked version of the Kenyan MOU caused an outcry as it gave the US unfettered access to Kenyan patient data in contravention of the country’s Data Protection Act, but sources close to the talks say that the MOU now confirms that it will be conducted within the parameters of this Act.

US businesses in Rwanda

There is less information about Rwanda’s deal from the US State Department with sources close to talks indicating that the Rwandan government pushed back against several of the US demands.

Rwanda stands to get up to $158 million over the next five years to address “HIV/AIDS, malaria, and other infectious diseases, and to bolster disease surveillance and outbreak response”. 

The MOU also “helps further American commercial interest in Rwanda and Africa more broadly” through support for two US companies, robotics manufacturer Zipline and biotech company Ginkgo Bioworks, which recently settled a class action suit after being accused of fraud.

“When developing the dozens of ‘America First Global Health Strategy’ bilateral agreements we will sign in the coming weeks, we always start with the principle that American sovereign resources should be used to bolster our allies and should never benefit groups unfriendly to the United States and our national interests,” said Jeremy Lewin, senior official for Foreign Assistance, Humanitarian Affairs  and Religious Freedom at the US State Department.

South Africa has not been invited to talks with the US over the resumption of aid despite having one of the highest HIV burdens in the world, with Trump recently repeating false claims that the country was involved in “genocide” against its white citizens.

ACIP committee vaccine Hep B
The influential Advisory Committee on Immunization Practices (ACIP) recommended delaying initial Hep B vaccine in newborns – reversing 35 years of policy.

A United States vaccine advisory panel, recently reformed to include known vaccine skeptics, voted to eliminate a three-decade-long recommendation that all newborns in the US receive a vaccine to protect against hepatitis B (Hep B) at birth –  a change that was denounced immediately by medical groups like the American Academy of Pediatrics and the American College of Physicians. The recommendation must be approved by the acting director of the Centers for Disease Control and Prevention (CDC). 

The Advisory Committee on Immunization Practices (ACIP), voted 8-3 to revise the US’s childhood immunization schedule for Hep B for the first time since 1991, saying that the shot is no longer necessary for babies born to mothers who test negative for the virus. 

Instead, ACIP recommended that parents delay the first dose to no earlier than two months – and consult with their doctors about whether and when to receive the vaccine.

ACIP vice-chair Robert Malone cited the “cumulative risk” of combined vaccines at birth as a reason for delaying vaccinations. 

But Malone has been criticized for vaccine misinformation. He is one of the new board members appointed by Health and Human Services Secretary Robert F. Kennedy Jr, a vaccine skeptic, following a “purge” of prior board members.

Medical experts urged the panel not to change the schedule 

vaccine Hep B cdc
A screenshot of the CDC’s website as of December 5, showing current evidence in support of Hep B vaccinations.

A long lineup of medical experts who provided feedback to the panel in two days of testimony strongly urged against changing the vaccination schedule, which has been credited with reducing Hep B infections by 99% in the US – preventing maternal to infant transmission of mostly-asymptomatic Hep B. Globally, the vaccine has prevented millions of infections, per Health Policy Watch’s related coverage.

“This vote is an unnecessary solution looking to find a problem to solve. It will only endanger children and increase risk of death for millions,” said Dr Jason Goldman, the President of the American College of Physicians in remarks to the Committee, whose proceedings were livestreamed.

“I would urge that we go back to our true experts who do this all the time, our CDC colleagues. They could have vetted this misinformation before it was presented to the public,” said hepatitis researcher Dr Amy Middleman pointing to discrepancies in remarks made by the Committee. 

The ACIP panel further recommended that instead of sticking to a set three-dose schedule, medical providers should test the antibody levels in infants to determine whether they should receive additional doses – when and if an initial Hep B dose is administered.

The problem with this approach, according to physicians, is that there is no implementation research or cost analysis of doing additional blood draws to back it up.  Without the jab, deadly and debilitating Hep B disease can be transmitted from asymptomatic mothers to newborns at birth who are not routinely screened under the patchwork of health insurance policies and systems that exist in the US today.  Moreover, toddlers and children can also become infected from more contact with infected blood or other bodily fluids at home or in school.

“We should do the studies first to determine if fewer doses are actually effective,” said Dr Judith Shlay, a family medicine specialist, in remarks to the committee. 

Republican senator speaks out against recommendation

It’s now up to the CDC Director Jim O’Neil to decide on whether to formally adopt the ACIP recommendation – and pressure on him is already building.

In a post on X, Senator Bill Cassidy (R-LA), a medical doctor and chair of the Senate Committee on Health, Education, Labor, and Pensions (HELP), urged the acting CDC director to reject the ACIP’s recommendations. Cassidy was a critical vote in confirming Kennedy’s appointment as Secretary of Health and Human Services. 

“As a liver doctor who has treated patients with hepatitis B for decades, this change to the vaccine schedule is a mistake. The hepatitis B vaccine is safe and effective,” he said in a post on X.

“Before the birth dose was recommended, 20,000 newborns a year were infected with hepatitis B. Now, it’s fewer than 20. Ending the recommendation for newborns makes it more likely the number of cases will begin to increase again. This makes America sicker,” he commented. 

Cassidy referred to the drop in US Hep B infections over the past three decades. Now, most cases of Hep B in the US occur in the Appalachian region, which suffers from a higher poverty rate compared to the rest of the country, according to CDC surveillance.

“Acting CDC Director O’Neill should not sign these new recommendations and instead retain the current, evidence-based approach,” Cassidy said. 

Image Credits: CDC.

Clinical trials
The African continent only accounts for 4% of clinical trials globally, jeopardizing the development of new medicines, and demonstrating the chronic underinvestment in the continent’s healthcare ecosystem.

In Kenya, toxicologists and epidemiologists face a difficult choice: to pursue better-paid work to support their families, or volunteer as reviewers for vaccine clinical trials, often without the compensation needed to cover even their children’s school fees.

Their dilemma underscores a broader challenge in Africa’s clinical research ecosystem. Slow, duplicative approval processes and limited regulatory capacity continue to deter sponsors from bringing trials to the continent. The continent accounts for 25% of the global disease burden, but just 4% of clinical trials

This “stark disparity” means that access to vaccines, diagnostics, and medicines is “not always guaranteed,” said Caxton Murira, a clinical research expert with the Science for Africa Foundation. 

Yet the continent also represents “enormous untapped potential” for the creation of effective and ethical medicines and vaccines, said Angelika Joos, science and regulatory policy executive at  Merck, and a panelist at the fourth and final event in a series at the annual Africa Regulatory Conference

“Africa is critical for advancing science and for ensuring that medicines work for everyone,” she said, addressing the recent webinar, hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). The four-part online conference focused on patient and community engagement, under-represented populations, innovative designs, and lastly, streamlining regulatory processes. 

Creating incentives for reviewers is one of the many ways experts have proposed to improve the continent’s regulatory system for clinical trials. To draw more clinical trials to Africa, panelists urged countries to  harmonize, simplify, and accelerate approvals for regulatory and ethics approvals across the continent. 

A ‘mismatch’ in the R&D pipeline

Africa continent clinical trials
Capacity fragmentation, poor visibility of resources, and a time-consuming regulatory process all hinder Africa’s clinical trial capabilities.

At the heart of the problem is chronic underinvestment. Funding for clinical research and development does not reflect Africa’s burden of disease, Murira noted. This gap spans both infectious diseases, such as malaria and tuberculosis, and noncommunicable diseases (NCDs) like diabetes and heart disease, which are rising as Africa’s population ages.

And while many countries have made significant progress in reducing infectious diseases, NCDs are often neglected in clinical research and trials, Murira argued. 

Globally, clinical trials exceeded $84 billion in market size in 2024, with every dollar invested in clinical research yielding a $405 return. Yet only 4% of the roughly 25,000 trials that occur each year take place on the African continent. 

This mismatch, driven by global market and industry strategies rather than local disease burden, jeopardizes the future of new medicines and demonstrates the chronic underinvestment in the continent’s healthcare ecosystem.  

Experts pointed to capacity fragmentation, poor visibility of resources, and a time-consuming regulatory process as worsening Africa’s clinical trial under-representation. Many countries can host clinical trials – beyond the usual hubs where funding is typically concentrated to such as South Africa, Egypt, Nigeria, Kenya, Ghana, and Tanzania. However, lesser-known sites struggle to compete with established centers.

Networks for collaboration

Clinical trial research Africa
Researchers across the continent, like those at Cape Town’s H3D Foundation, benefit from online platforms that raise the visibility of potential clinical trial sites.

To enhance this visibility, the South African-based start-up, nuvoteQ, has set up an interactive online platform called the Clinical Trials Community (CTC) Africa

CTC aims to attract investment in African clinical trials by showcasing the continent’s clinical trialists and research sites, said CEO Adriaan Kruger. 

It is an “interactive platform” that provides a registry of sites, data on site feasibility, and access to country-specific regulatory and ethics information to make it easier for sponsors to find and partner with African research locations. 

“We actively work on providing and building a financially sustainable model so that we can keep these platforms running in the long term,” said Kruger, noting that past initiatives have failed to gain traction.

Efforts to enhance visibility and partnerships are already underway regionally. The Science for Africa Foundation, headquartered in Nairobi, has mapped over 3,500 clinical trial centers, regulatory boards in 55 countries, and 196 ethics committees. The goal, Murira said, is to improve visibility while highlighting gaps that need investment.

“We’ve shifted from asking, ‘What’s your research capacity?’ to ‘How can we use what you have to position you to be a leader on the African continent?’” said Murira, who heads the foundation’s clinical trials and research portfolio. 

Standardizing the process 

Clinical trials IFPMA regulatory conference
Panelists at the final Africa Regulatory Conference discuss potential solutions to optimize clinical trial approvals.

Aside from finding suitable sites for trials, researchers or pharmaceutical companies looking to recruit patients into clinical trials find that the approval process can be duplicative, ineffective, and expensive, said Joos. 

These delays hinder patient access to innovative treatments, and deter researchers from attempting more trials.

Bioethicist Keymanthri Moodley, an emeritus professor at Stellenbosch University, highlighted the lack of standardization – and trust – between research approval boards as impeding the process. 

“One research committee does not trust the competency of another,” Moodley argued. So if malaria vaccine researchers wanted to recruit participants across a national border, they could run into months-long delays for approvals from both countries. Furthermore, both researchers and reviewers are in need of training. 

“We have the tools but we need standardization,” said Moodley, pointing to World Health Organization’s (WHO) Global Benchmarking Tool (GBT) as a helpful metric for evaluating national regulatory authorities (NRAs). 

“There has been so much development at the theoretical level. But the area where we experience challenges is implementation. The continent is heterogeneous. Every country is different, but in general, very few resources are allocated to regulatory authorities and research ethics committees. And so we were always complaining about delays in regulatory approval,” said Moodley, who also served as founding director of a WHO Collaborating Centre in Bioethics.

David Mukanga, deputy director for Africa regulatory systems at the Gates Foundation, echoed these concerns, saying that as research ethics committee members are not paid to review trials, they are placed in a difficult position. 

“If you review 30 protocols in five years, it doesn’t count towards your promotion,” he said. But supervising a PhD student does.” 

This leaves academics juggling teaching loads, exams, and financial pressures while trying to support essential ethical reviews. 

“There needs to be creative incentives for people to be able to commit time and be recognized for their good work in supporting reviews,” he said.

Reducing duplication through regulatory reliance

One solution gaining attention is regulatory reliance – the concept that one country’s drug regulator uses the scientific assessments of another trusted authority. This, in turn, could reduce redundant reviews and shorten approval timelines.

“Leveraging trusted national regulatory assessments reduces duplication, speeds approvals, and fosters collaboration,” said Lada Leyens, a senior director at the pharmaceutical company Takeda. 

The UK’s medicines regulator recently introduced a clinical trial reliance pathway allowing approvals within two weeks when a trusted authority has already assessed the application, Leyens noted. For under-resourced African regulators facing staff shortages and high turnover, reliance could significantly shorten timelines.

Africa’s future

For those working to improve the clinical research and trials ecosystem in Africa, enhancing the visibility of capacity, fostering trust between researchers, regulators, sponsors, and the community, and increasing investments in ethical clinical trials in Africa all remain critical goals. 

“We need to build the capabilities now and the capacities now to position Africa as a key player in the next decade of this global health innovation. It’s about equity, it’s about scientific progress, and it’s about preparing Africa for the future,” remarked Joos. 

 

The webinar, Streamlining regulatory and ethics approvals, was the fourth of a four-part online African Regulatory Conference hosted by IFPMA. All four sessions were recorded and available for viewing.

Image Credits: Eugene Kabambi/ WHO, IFPMA.

San Francisco City Attorney David Chiu briefs the media about the case on Tuesday.

The City of San Francisco has filed a historic lawsuit against 10 ultra-processed food (UPF) manufacturers, seeking “restitution and civil penalties” to help local governments to “offset astronomical health care costs associated with UPF consumption”.

The 10 companies are Kraft Heinz Company, Mondelez International, Post Holdings, The Coca-Cola Company, PepsiCo, General Mills, Nestle USA, Kellogg, Mars Incorporated, and ConAgra Brands, which make the bulk of UPF in the US.

The first-of-its-kind lawsuit, filed on Tuesday on behalf of the people of the State of California, alleges that the companies used “unfair and deceptive acts” to sell and market their products, violating California’s Unfair Competition Law and public nuisance statute. 

Aside from restitution, the City wants the companies to stop using “deceptive marketing” and “take action to correct or lessen the effects of their behavior”. 

“This case is about food products whose ingredients and manufacturing processes interrupt our bodies’ abilities to function. It is about the Defendants – gigantic food conglomerates, all – who designed, manufactured, marketed, and sold these foods knowing they were dangerous for human consumption,” the City argues.

San Francisco City Attorney David Chiu told a media briefing: “They took food and made it unrecognisable and harmful to the human body.”

Comparing the UPF companies’ tactics to those used by tobacco companies, Chui said: “We must be clear that this is not about consumers making better choices. Recent surveys show Americans want to avoid ultra-processed foods, but we are inundated by them. These companies engineered a public health crisis, they profited handsomely, and now they need to take responsibility for the harm they have caused.”

Some of the UPF targeted by the City of San Francisco.

UPF stimulates cravings

San Francisco Mayor Daniel Lurie added: “San Francisco families deserve to know what’s in their food. We’re not going to let our residents be misled about the products in our grocery stores. We are going to stand up for public health and give parents the information they need to keep themselves and their kids safe and healthy.”

The court papers define UPF as “former whole foods that have been broken down, chemically modified, combined with additives, and then reassembled using industrial techniques such as molding, extrusion, and pressurization. 

Some contain additives unique to UPF, including “colors, flavor enhancers, emulsifiers, artificial sweeteners, thickeners, and foaming, anti-foaming, bulking, and gelling agents”. 

These foods are a “combination of chemicals designed to stimulate cravings and encourage overconsumption”. UPF makes up some 70% of food consumed in the US.

The consumption of UPF has been linked to Type 2 diabetes, fatty liver disease, cardiovascular disease, colorectal cancer, and depression.

Protecting communities

“This lawsuit is a critical step toward protecting the health of our communities,” said San Francisco Director of Health Daniel Tsai. “For decades, ultra-processed foods have reshaped our diets. 

“These products are not just unhealthy, they are engineered to be addictive, disproportionately harm low-income communities and communities of color, and contribute to rising rates of chronic illness like diabetes, heart disease, and cancer,”  said San Francisco Director of Health Daniel Tsai.

The City’s court papers also argue that UPF marketing campaigns “disproportionately targeted Black and Latino children, who have been targeted with 70% more ads for ultra-processed foods than their white counterparts”.

The prevalence of diabetes among Black Americans has quadrupled in the past 30 years, and Black Americans are 70% more likely to develop diabetes than White Americans, according to the court papers.

Largest review of UPF

The aggressive marketing of ultra-processed food is one of the drivers of children’s rising obesity.

The court case, the first such action by a municipality, comes a few weeks after the world’s largest review of UPF was published in The Lancet.

The three-part review argues that the rise in UPF “is driven by powerful global corporations who employ sophisticated political tactics to protect and maximise profits”. 

The review stresses that education aimed at individual behaviour change is not enough: “Deteriorating diets are an urgent public health threat that requires coordinated policies and advocacy to regulate and reduce ultra-processed foods and improve access to fresh and minimally processed foods.”

The series provides hundreds of studies to prove its thesis that UPF is displacing long-established dietary patterns centred on whole foods, and this is “a key driver of the escalating global burden of multiple diet-related chronic diseases”.

Using evidence from national food intake surveys, large cohorts, and interventional studies, the review highlights global patterns of “gross nutrient imbalances”. It shows that overeating is driven by the “high energy density, hyper-palatability, soft texture, and disrupted food matrices” of UPFs, and the rise of UPF has led to the consumption of “toxic compounds, endocrine disruptors, and potentially harmful classes and mixtures of food additives”.

The Lancet editorial published alongside the review notes that “the rise of UPFs in human diets is damaging public health, fuelling chronic diseases worldwide, and deepening health inequalities”.

“Addressing this challenge requires a unified global response that confronts corporate power and transforms food systems to promote healthier, more sustainable diets.”

The series advocates for a food system based on local food producers, preserving cultural foods and ensuring economic benefits for communities.

Image Credits: City of San Francisco.

Ozempic injection obesity
The widely popular weight loss drugs were recommended for obesity treatment by the WHO, a first for the global agency.

First-ever WHO guidelines recommending the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults has been issued by the World Health Organization – in what the global health agency said is a “conditional” sign of approval for the cutting edge medications that have become widely popular. 

The new WHO recommendations go well beyond those of its Essential Medicines List (EML) issued in September, which recommended the drugs only for diabetes. 

And the guidelines should have widespread ramifications for policy decisions in countries where the drugs have not yet been approved. Worldwide, more than one billion people are obese, leaving individuals susceptible to a host of health conditions like diabetes, heart disease, and some cancers. 

The highly-sought after drugs, sold under brand names like Wegovy®, Ozempic®, and Zepbound® in the United States, were initially only recommended by WHO for the treatment of Type II diabetes in the EML. In September, the active ingredients of these drugs – not the brand names – were added to the WHO’s Essential Medicines List – which guides national health systems in making medicine procurement decisions

Recognizes obesity is a chronic disease

 “The new guidance recognizes that obesity is a chronic disease that can be treated with comprehensive and lifelong care,” said WHO Director General Dr Tedros Adhanom Ghebreyesus, in a statement. “While medication alone won’t solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms.”

The WHO did qualify its recommendations, saying endorsement “is conditional due to limited data on their long-term efficacy and safety, maintenance and discontinuation, their current costs, inadequate health-system preparedness, and potential equity implications.”

The drugs should not be used by pregnant women, and should be paired with evidence-based interventions like healthy diets and physical activity, the guidelines also stress. 

Need to assure equitable access

Obesity GLP-1 drugs US
The US comprises the lionshare of GLP-1 drug consumption, with states debating whether to shoulder the costs for Medicare recipients.

With US consumers comprising nearly 75% of current GLP-1 demand worldwide, the “greatest concern is equitable access” to the new treatments, said Tedros, speaking with journalists earlier this week. 

“Without concerted action, these medicines could contribute to widening the gap between the rich and poor, both between and within countries,” he added. 

And even with ramped up production, these drugs would likely only reach 10% of adults who could benefit from GLP medications in the next five years, the WHO said in a press release. Their guidelines recommended that countries and pharma companies implement several strategies to try to expand access, such as pooled procurement, tiered pricing, and voluntary licensing of what are now patented formulations to local manufacturers. 

Writing in the Journal of the American Medical Association (JAMA), this week, a team of WHO directors and advisors argued that “the availability of GLP-1 therapies should galvanize the global community to build a fair, integrated, and sustainable obesity ecosystem.”

Nearly one in five Americans have used a GLP-1 therapy at least once. And nearly one in eight are currently on the medication. Thirteen states already cover the drugs under Medicaid programmes, despite the enormous up-front cost – with others considering coverage.

While the US currently dominates GLP-1 sales, EU countries, China, and India are expected to make up more of the demand for these drugs in the coming years.

So the question remains whether lower-and-middle income countries, which are facing their own accelerating obesity rates, will have the same level of access. These countries still face barriers to basic diabetes care, the initial intent of use of GLP-1 drugs. 

‘Medication alone won’t solve the obesity crisis’

UNICEF and other international agencies singled out the aggressive marketing of ultra-processed food as a driver of rising obesity, especially in children.

Despite the excitement and potential of these drugs, the WHO cautioned that obesity treatment still must be paired with healthy diets and physical activity. 

“Medication alone will not solve the obesity crisis,” said Tedros. “Obesity is a complex disease that requires comprehensive, lifelong care. And it has many social, commercial and environmental determinants, requiring action in many sectors – not only in the clinic.”

These other determinants of obesity, such as a food environment rich in high sugar, fat, and salt foods, mean that the global overweight or obese population is expected to reach 60% by 2050.

Countries in Sub-Saharan Africa, the Middle East, and Latin America will be particularly affected by this surge. 

“Obesity is largely preventable,” said the WHO’s assistant director-general for health promotion and disease prevention, Jeremy Farr. “Yet millions of people around the world face environments that make it easier to gain weight and harder to stay healthy.”

Image Credits: David Trinks, KFF.

The IQ of Indian children exposed to high levels of air pollution was lower than children in areas with low air pollution.

Air pollution not only affects lung health but also brain development in children, according to two studies presented at the World Conference on Lung Health (WCLH) held in Denmark recently.

One study from India found that children living in highly polluted areas scored nearly 20 points lower on the intelligence quotient (IQ) than their peers in cleaner environments, immediately limiting their educational potential and life opportunities.

These findings highlight air pollution as not merely an environmental issue but a global health emergency that threatens children’s futures and severely worsens existing lung disease.

Air quality lowers IQ in children

Zeroing in on the link between airborne particulate matter and cognitive ability, new findings from the Kalinga Institute of Industrial Technology (KIIT) in India suggest a significant and close association between children’s IQ development and long-term exposure to ambient air pollution.

The KIIT study, published in the WCLH abstract book, examined the impact of particulate matter PM2.5 and PM10 (particulate matter with a diameter of 2.5 and 10 micrometres) on the cognitive development of children aged 6-8 in the state of Odisha in India. While the effects of air pollution on lung and cardiovascular health are well documented, this research represents a pioneeringl look into its potential to disrupt cognitive development in children.

Setting up a comparative analytical study, researchers assessed two sites between July and December 2022: one with high pollution levels (PM10 above 60 micrograms per cubic metre and PM2.5 above 40 micrograms) and one with low pollution. Children who had lived within a 1.5 km radius of air quality monitoring stations for six years were tested, using Malin’s Intelligence Scale for Indian Children, which measures full-scale, verbal, and performance IQ.

The results were stark. Mean Full-Scale IQ in high-pollution areas was 80.33 compared to 98.12 in low-pollution areas. Children from high-pollution areas had a verbal IQ of 81.60 compared to 99.68 in low-pollution areas, and a performance IQ of 79.02 compared to 96.55 in cleaner areas.

The authors conclude that long-term exposure to air pollution is closely linked to poorer cognitive development in children. The report further suggested that the child’s age and weight, poor kitchen ventilation, maternal education, and family income also made an impact on full-scale IQ, painting a picture of multiple interacting risk factors.

Air pollution affects the poorest the most

“The burden of air pollution and climate change on health is one which sadly continues to grow. And, as with many other determinants of health, it is the world’s poorest who are the most affected,” said Professor Guy Marks, president of the International Union Against Tuberculosis and Lung Disease (The Union).

“New strategies are urgently needed globally to ensure no one’s future is limited simply because of the air they breathe.”

The Union was established in 1920 as the world’s first global health organisation and works towards a world free of tuberculosis and lung disease. Its members, staff, and consultants work in more than 140 countries globally. 

Asthma attacks increase in West Africa

Separately, a direct link between air pollution and the severity of asthmatic conditions in adolescents has been reported in a new study by the Centre Hospitalier et Universitaire de Pneumo-Phtisiologie (CNHUPPC) in Cotonou, Benin, in West Africa.

In Cotonou, where air pollution systematically exceeds World Health Organisation (WHO) thresholds for all pollutants, researchers followed a cohort of 730 asthmatic adolescents over 36 months. The study reported that over one-third 37% of the adolescents experienced at least one respiratory event or asthma attack.

Measuring individual exposure via portable air quality sensors carried in backpacks and fixed sensors in schools and homes, the researchers determined that the adolescents with frequent respiratory events had higher levels of exposure to several pollutants, including nitrogen dioxide, PM1, PM2.5 and PM10. 

The study also noted that asthma symptoms occurred 2.5 times more during the seasonal harmattan period when a cool, dry and dusty wind blows, usually between December and March. This highlights the compounding effect of climate-related atmospheric changes. 

“Fine particulate air pollution remains very high in West Africa and poses a serious risk to the respiratory health of adolescents with asthma who are chronically exposed,” said Dr Attannon Arnauld Fiogbé, chest physician and clinical researcher at CNHUPPC. He suggested that strengthening responses by combining air quality alerts with therapeutic education could significantly improve respiratory health.

Air purifiers in schools 

Proposing a tangible solution to mitigate some of the exposure, Professor Anant Sudarshan from the University of Warwick in the UK, advocates for targeted intervention in schools, especially for low-income communities. 

“Introducing appropriately sized air purifiers in all government schools may be a good policy. Children spend a significant share of their day in classrooms, and any reduction in pollution exposure can have large health benefits,” Sudarshan told Health Policy Watch. 

“This is most important for the poor who cannot afford to purify air at home or who live close to traffic or industry,” Sudarshan added.

Sudarshan explained that children spend roughly one-third of their day at school for two-thirds of the year – around 17% of their lives – so cleaning up the air just in schools could cut a child’s annual pollution exposure by approximately 17%.

This reduction is considered vital because PM2.5 has been shown to have similar effects on cognitive behaviour and productivity as CO2 buildup, impacting both short-term alertness and long-term development. 

For policymakers grappling with this crisis, the evidence is now clear: the fight for lung health must integrate immediate, robust action to protect the cognitive and life-long potential of the world’s children.

Image Credits: Akshar Dave/ Unsplash.